Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Cardiovascular Organoids With Adjustable Endothelial Composition via SOX17-Engineered hPSCs.

Biotechnology and bioengineering·2026
Same author

The Access, Initiation, Engagement, Retention, and Recovery (AIERR) Model: A Stage-Based Framework for Understanding Mental Health Service Utilization.

Healthcare (Basel, Switzerland)·2026
Same author

CAR-neutrophils produced in vivo to treat glioma.

Nature biomedical engineering·2026
Same author

Experimental evaluation of skin contact pressure and thermal injury risk with radiant heaters in electric vehicles.

Journal of thermal biology·2026
Same author

scChat: A Large Language Model-Powered Co-Pilot for Contextualized Single-Cell RNA Sequencing Analysis.

AIChE journal. American Institute of Chemical Engineers·2026
Same author

Event-Based Referred Vibrotactile Feedback for Bare-Hand XR Interaction.

IEEE transactions on visualization and computer graphics·2026

相关实验视频

Updated: Jun 15, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

842

工程CAR-T疗法用于增强固体瘤向.

Danqing Zhu1,2, Won Joon Kim1, Hyunjin Lee3

  • 1Department of Chemical and Biological Engineering, School of Engineering, The Hong Kong University of Science and Technology (HKUST), Kowloon, Hong Kong SAR, 999077, China.

Advanced materials (Deerfield Beach, Fla.)
|January 2, 2025
PubMed
概括

化学抗原受体 (CAR) -T细胞疗法通过提高T细胞的特异性和克服瘤微环境挑战,对固体瘤显示出前景. 新的工程策略和验证平台是推动CAR-T疗法的关键,以改善癌症治疗.

关键词:
化学抗原受体 (CAR) 是一种癌症免疫疗法免疫疗法药物输送是药物输送的过程.纳米颗粒是一种纳米粒子.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

470
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.2K

相关实验视频

Last Updated: Jun 15, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

842
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

470
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.2K

科学领域:

  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学
  • 生物技术是生物技术.

背景情况:

  • 化学抗原受体 (CAR) -T细胞疗法是癌症免疫疗法的突破,特别有效于对抗血液性恶性瘤.
  • 然而,由于抗原异质性和复杂的瘤微环境 (TME) 等挑战,其在构成绝大多数癌症的固体瘤中的有效性仍然有限.

研究的目的:

  • 本综述探讨了创新的策略,以加强对固体瘤的CAR-T细胞疗法.
  • 它的重点是提高T细胞的特异性,解决分娩和体内重编程的挑战,并探索先进的验证平台.

主要方法:

  • 探索实验和计算策略,包括蛋白质工程和机器学习,以提高T细胞的特异性.
  • 对固体瘤的T细胞输送和体内重编程技术的讨论.
  • 研究工程有机体系统作为TME的高保真体外模型,用于CAR发现和验证.

主要成果:

  • 最近的临床试验显示,像神经母细胞瘤和胃肠道癌等固体瘤对CAR-T治疗有一定的反应性.
  • 工程器官系统正在成为模仿TME和验证CAR设计的强大工具.
  • 在CAR设计和验证平台的进步对于克服固体瘤挑战至关重要.

结论:

  • 创新的工程策略具有显著的潜力,可以增强对固体瘤的CAR-T细胞治疗.
  • 这些进展旨在彻底改变下一代CAR-T疗法,从而为更广泛的癌症提供更有效的治疗方法.
  • 克服TME复杂性和改善T细胞向对于未来的成功至关重要.